ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc (AVIR)

3.44
0.02
(0.58%)
Closed June 22 4:00PM
3.44
0.00
(0.00%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
3.44
Bid
3.38
Ask
3.69
Volume
641,153
3.36 Day's Range 3.61
2.765 52 Week Range 4.60
Market Cap
Previous Close
3.42
Open
3.43
Last Trade
6
@
3.44
Last Trade Time
Financial Volume
$ 2,198,090
VWAP
3.4283
Average Volume (3m)
246,996
Shares Outstanding
84,223,100
Dividend Yield
-
PE Ratio
-2.13
Earnings Per Share (EPS)
-1.61
Revenue
-
Net Profit
-135.96M

About Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treat... Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Atea Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVIR. The last closing price for Atea Pharmaceuticals was $3.42. Over the last year, Atea Pharmaceuticals shares have traded in a share price range of $ 2.765 to $ 4.60.

Atea Pharmaceuticals currently has 84,223,100 shares outstanding. The market capitalization of Atea Pharmaceuticals is $289.73 million. Atea Pharmaceuticals has a price to earnings ratio (PE ratio) of -2.13.

AVIR Latest News

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with...

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.26-7.027027027033.73.743.362776003.51788651CS
4-0.27-7.277628032353.714.0053.362614023.69841691CS
12-0.56-1444.13993.362469963.75696613CS
260.4314.28571428573.014.63.013664073.84206155CS
52-0.56-1444.62.7653792193.53560214CS
156-19.91-85.267665952923.3546.90992.765100839212.82401462CS
260-26.5-88.510354041429.9494.17372.76593998315.42527582CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

AVIR Discussion

View Posts
DewDiligence DewDiligence 1 month ago
AVIR 1Q24 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500150.html

3/31/24 cash = $542M, down from $578M at 12/31/23.

Final results from the phase-3 SUNRISE COVID trial are expected in 2H24 (no change relative to the prior guidance). There are no interim analyses (#msg-174125019).
👍️0
Monksdream Monksdream 2 months ago
AVIR under $5
👍️0
DewDiligence DewDiligence 3 months ago
AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:

https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html Atea Pharmaceuticals…today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort… The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. The two planned interim analyses have been canceled: “Since full enrollment was achieved ahead of the two planned interim analyses for safety and futility by the Data Safety Monitoring Board (DSMB), the analyses are no longer relevant, and in agreement with the DSMB, we will proceed to the full analysis of the trial. We look forward to reporting SUNRISE-3 results in the second half of 2024…
👍️0
DewDiligence DewDiligence 4 months ago
AVIR phase-3 COVID update:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-fourth-quarter-210500983.html

The first and second interim analyses in the phase-3 COVID trial will be performed in March and in 2Q24, respectively, and the final results will be available in 2H24. 1,400 patients have been enrolled in the bemnifosbuvir monotherapy cohort (the cohort that the primary endpoint is based on).

AVIR had $578M of cash at 12/31/23, which is why they can afford to blow so much money on a longshot trial.
👍️0
DewDiligence DewDiligence 1 year ago
AVIR rejects Tang buyout offer, as expected:

https://www.globenewswire.com/news-release/2023/05/30/2678205/0/en/Atea-Pharmaceuticals%5B%E2%80%A6%5DTang-Capital-Partners-Affiliate-Concentra-Biosciences.html

The offer was for less than AVIR’s cash value.
👍️0
DewDiligence DewDiligence 1 year ago
It's not a serious offering for the reason mentioned in #msg-171974875.
👍️0
mwn mwn 1 year ago
Why is the sp going so far below the offering?
👍️0
DewDiligence DewDiligence 1 year ago
Yes.
👍️0
Paullee Paullee 1 year ago
Did you not notice that a CVR of 80% is included in the package?
👍️0
DewDiligence DewDiligence 1 year ago
In other words, AVIR could do better than $5.75/sh by simply liquidating.
👍️0
DewDiligence DewDiligence 1 year ago
AVIR acknowledges Tang buyout offer—makes_no_recommendation_to_shareholders—(yet):

https://www.globenewswire.com/news-release/2023/05/23/2674788/0/en/Atea-Pharmaceuticals-Confirms-Receipt-of-Unsolicited-Proposal-from-Tang-Capital-Partners-Affiliate-Concentra-Biosciences.html

Even thought Tang’s $5.75/sh offer is a big premium to where AVIR was trading prior to the offer, it’s less than AVIR’s cash value per share. Hence, it’s hard to see how AVIR’s BoD could accept the offer. They could make a counter-proposal, of course.
👍️0
DewDiligence DewDiligence 1 year ago
Tang Capital makes_unsolicited AVIR buyout offer@$5.75/sh +CVR—a_55%_premium_to_Friday’s_close:

https://www.sec.gov/Archives/edgar/data/1593899/000121465923007616/z519230sc13d.htm (scan to bottom)

Why does Tang want to acquire AVIR? Presumably for AVIR’s COVID drug, AT-527, such as it is. AT-527 is a polymerase inhibitor that is similar to an HCV drug BMY dropped several years ago due to toxicity. AVIR is conducting a phase-3 trial in high-risk COVID patients using a daily dose of 1100 mg (550mg BID); the trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT05629962 .
👍️0
Awl416 Awl416 1 year ago
Volume
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 1Q23 CC transcript:

https://finance.yahoo.com/news/q1-2023-atea-pharmaceuticals-inc-140930636.html
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 1Q23 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500951.html

3/31/23 cash = $621M.
👍️0
V63 V63 1 year ago
So AVIR beat its earnings, and now it might bump up a little tomorrow.
👍️0
DewDiligence DewDiligence 1 year ago
AVIR reports final data from phase-2 COVID trial:

https://www.globenewswire.com/news-release/2023/04/12/2645185/0/en/Atea-Announces-Presentation-of-Bemnifosbuvir-Data-Demonstrating-Reduced-Hospitalizations-for-COVID-19-Patients-at-2023-European-Congress-of-Clinical-Microbiology-Infectious-Disease.html
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 4Q22 CC transcript:

https://finance.yahoo.com/news/atea-pharmaceuticals-inc-nasdaq-avir-022000995.html
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 4Q22 results—12/31/22 cash=$647M:

https://www.globenewswire.com/news-release/2023/02/28/2617674/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

AVIR expects the interim analysis of the SUNRISE-3 (COVID) phase-3 trial to occur in 2H23. One possible outcome of the interim analysis is increasing the number of patients to provide more statistical power for the final analysis.
👍️0
DewDiligence DewDiligence 1 year ago
AVIR JPM webcast slides:

https://ir.ateapharma.com/static-files/731c461d-37e4-4364-8a12-eb605580b0aa
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 2023 newsflow:

https://finance.yahoo.com/news/atea-pharmaceuticals-highlights-strategic-priorities-120000077.html
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 3Q22 results—9/30/22 cash=$665M:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-third-quarter-210500282.html

A phase-3 trial of Bemnifosbuvir (f/k/a AT-527) in 1,500 high-risk, non-hospitalized COVID patients is expected to start by the end of 2022. AVIR is defining “high-risk” as: a) age 80+; b) age 65+ with 1 or more major risk factors; or c) an immunocompromised adult of any age.

The daily dose of Bemnifosbuvir is a whopping 1100mg (550mg BID).
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 2Q22 results—6/30/22_cash=$684.5M (down from $705.5M at 3/31/22):

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500782.html
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 3/31/22 cash=$705.5M—burning $58.9M in 1Q22...

1Q22 PR:
https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-103000747.html

1Q22 CC slides:
https://ir.ateapharma.com/static-files/8a966559-367b-4a3b-96c0-ff21958c0562
👍️0
DewDiligence DewDiligence 3 years ago
LOL re AVIR’s attempt to be relevant:

https://www.globenewswire.com/news-release/2021/12/14/2352116/0/en/Atea-Pharmaceuticals-Introduces-New-Strategic-Clinical-Development-Program-for-AT-527-in-COVID-19.html
👍️0
Jake L Jake L 3 years ago
AVIR - Friday Rundown, Monday Expectations

👍️0
Wallst_junkie Wallst_junkie 3 years ago
Watching for a uptrend
👍️0
dealerschool2006 dealerschool2006 3 years ago
GOOD JOB!!! ya, by the time I discovered AVIR it had gone up 50% from the bottom...
👍️0
crudeoil24 crudeoil24 3 years ago
Wow! That's why you don't hold these Pharma overnight.

AVIR
👍️0
TheFinalCD TheFinalCD 3 years ago
wow went sub $11 and traded the whole float, shit it traded the whole OS 1.5x today https://finviz.com/quote.ashx?t=AVIR
👍️0
DewDiligence DewDiligence 3 years ago
Why AVIR's AT-527 program is no-go: #msg-166425975.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 3 years ago
David v Goliath

Interesting article - check out RDHL

https://www.yahoo.com/entertainment/david-v-goliath-race-develop-123328764.html
👍️0
Chess Master Chess Master 3 years ago
What a drop
👍️0
ecommceo ecommceo 3 years ago
Way over sold here.
👍️0
Planopenny Planopenny 3 years ago
Out at $16, easy $$$
👍️0
Docstemcell2020 Docstemcell2020 3 years ago
Let's go Brandon! FJB :)
👍️0
DewDiligence DewDiligence 3 years ago
AVIR CC slides (largely BS, IMO):

https://ir.ateapharma.com/static-files/d72bd065-82b3-4eeb-ad3a-40c5518d66d6
👍️0
Planopenny Planopenny 3 years ago
In at $10
👍️0
rosemountbomber rosemountbomber 3 years ago
Well the shit just hit the fan. Didn’t meet primary in study. Stock dow $28
👍️0
rosemountbomber rosemountbomber 3 years ago
Thanks DD
👍️0
DewDiligence DewDiligence 3 years ago
The primary endpoint in MRK’s molnupiravir trial was the proportion of patients, relative to placebo, who died or needed hospitalization within 28 days:

https://clinicaltrials.gov/ct2/show/NCT04575597
👍️0
rosemountbomber rosemountbomber 3 years ago
So I have to confess to my ignorance when it comes to anti-viral clinical trials. It appears that the primary outcome studied in the AT-527 phase 3 trial is evaluated using a Covid 19 Symptom Diary. It does not sound like it is something very precise when asking a patient to score themselves on these 12 questions (which I have not exactly found yet).

But my question is, did the Merck drug molnupiravir get tested using this same method (symptom diary)? It must have been more than that at least as they also measure deaths, etc. - although that may have been secondary outcomes.
👍️0
Whalatane Whalatane 3 years ago
AVIR presentation tomorrow Oct 5th

https://newsfilter.io/articles/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines--infectious-day-conference-42a958b2016103f267b2f6525ac4ac0c

Kiwi
👍️0
crudeoil24 crudeoil24 3 years ago
You bet! > AVIR up 45% @ 50.05
👍️0
Whalatane Whalatane 3 years ago
Thx for the updates

Kiwi
👍️0
crudeoil24 crudeoil24 3 years ago
AVIR up 45% @ 50.05 > premarket.
👍️0
crudeoil24 crudeoil24 3 years ago
AVIR > 53M share trading float.
👍️0
crudeoil24 crudeoil24 3 years ago
Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference
7:00 am ET September 29, 2021 (Globe Newswire) Print
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Tuesday, October 5, 2021 at 9:30 a.m. ET.

A live webcast of the presentation will be available here and on the Company's website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes

SVP, Investor Relations and Corporate Communications

617-818-2985

Barnes.jonae@ateapharma.com
👍️0
crudeoil24 crudeoil24 3 years ago
AVIR up 30% @ 45.00 > As Barron's reported in a magazine feature earlier this month , the pills have the potential to play an enormous role as the world adapts to an endemic threat from Covid-19. Even if the antivirals from Merck, Pfizer, the biotech Atea Pharmaceuticals (AVIR), and others, are only moderately effective, they are likely to be in enormous demand globally as patients and governments seek to blunt the human toll of the virus.
👍️0
DewDiligence DewDiligence 3 years ago
The stock is overvalued, IMO.
👍️0

Your Recent History

Delayed Upgrade Clock